Tumeurs bénignes du foie
Revu par Dr Toni Hazell, MRCGPDernière mise à jour par Dr Hayley Willacy, FRCGP Dernière mise à jour 29 déc. 2022
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Version audio
- Ajouter aux sources préférées sur Google
Professionnels de la santé
Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de la santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver l'un de nos articles de santé plus utile.
Liver tumours are benign or malignant; malignant tumours can be primary or secondary. In Europe and the USA, a solitary lesion in the liver is more likely to be a metastatic carcinoma than a primary liver tumour.
Risk factors for liver cancer1
The major risk factors for liver cancer are infection with hepatitis B and C and heavy alcohol consumption, all of which can cause cirrhosis. Smokers and those with diabetes are also at increased risk, while consumption of foods contaminated with aflatoxin is a cause of liver cancer in many developing countries.
Voir également le document séparé Cancer primitif du foie et Secondary Liver Cancer articles.
Haemangioma
The most common benign liver tumour in adults and children. They are more common in the right lobe of the liver than in the left lobe.
Hepatic haemangiomas can occur as part of a clinical syndrome - eg, Klippel-Trénaunay-Weber syndrome, Syndrome d'Osler-Weber-Rendu et Maladie de Von Hippel-Lindau.
The vast majority of hepatic haemangiomas are asymptomatic and most often discovered incidentally during imaging investigations for unrelated health concerns.2
Large cavernous haemangiomas may reach 8-10 cm in diameter.
They are thought to be congenital and may enlarge under the influence of oral contraceptives.3 However, they usually regress when oral contraceptives are stopped. They can also grow during pregnancy.
Hepatic haemangiomas may be seen in up to 10% of children aged 1 year but they usually regress within the first two years of life.
Haemangioma symptoms4
Usually small and asymptomatic; they most often present as incidental findings at the time of imaging of the liver, laparotomy or post-mortem.
Right upper quadrant pain or fullness is the most common symptom.
Examination is usually normal but there may be hepatomegaly and/or an arterial bruit over the right upper quadrant.
Rare presentations include a large abdominal mass, high-output cardiac failure, obstructive jaundice, gastrointestinal haemorrhage or fever. Thrombocytopenia, hypofibrinogenaemia and microangiopathic haemolytic anaemia may rarely occur.
Large lesions may cause obstruction to gastric emptying and so present with vomiting.
Rupture is rare but may occur spontaneously, following trauma or at the time of attempted biopsy.
Enquêtes
Imaging techniques include ultrasound, contrast-enhanced CT scanning, nuclear medicine studies using technetium 99m Tc-labelled red blood cells, MRI, hepatic arteriography and digital subtraction angiography.
Haemangioma treatment5
If asymptomatic they may be left alone. Surgical resection is the treatment of choice if necessary. Minimally invasive therapies include arterial embolisation, radiofrequency ablation and hepatic irradiation. Liver transplantation is required on rare occasions. Steroids and interferon treatment are other treatment options.
Hepatic adenoma
Hepatic adenomas are rare, benign liver tumours. Approximately 90% of cases occur in females, mostly aged 15-45 years. They occur most often in women of childbearing age and are strongly associated with the use of oral contraceptives.
Usually asymptomatic but may cause slight abdominal pain in the epigastrium and in the right hypochondrium, and also bloating. May cause elevations of gamma GT and alkaline phosphatase. The possibility of malignant transformation can be monitored with serum alpha-fetoprotein (AFP).6
Other conditions associated with hepatic adenomas include:
Anabolic steroids.7
Beta-thalassaemia.
Tyrosinaemia.
Diabète de type 1.
Glycogen storage diseases (types 1 and 3). Multiple hepatic adenomas are more common in glycogen storage disease.
The risk of malignant transformation is not completely known and may be as high as 13%.
Hepatic adenoma symptoms8
Often asymptomatic and found incidentally on physical examination or during imaging for another reason.
May present with pain in the right upper quadrant or the epigastric region.
A palpable mass may be noticed by the patient.
May present with severe, acute abdominal pain with bleeding into the abdomen, leading to shock.
Other rare presentations include obstructive jaundice.
Enquêtes
Liver function is not usually affected but aminotransferase levels may be mildly elevated or there may be features suggestive of obstructive jaundice.
The most appropriate imaging investigation is contrast-enhanced MRI.9
Immediate abdominal imaging is required for patients with hepatocellular adenomas who present with new or worsened abdominal pain or signs of haemodynamic instability.
Hepatic adenoma treatment10
Patients should be managed in referral centres with access to an MDT. They should be advised to stop using oral contraceptives or anabolic steroids. Pregnancy should be avoided until resection of the tumour because of the risk of growth and rupture.
Symptomatic tumours should be resected. Due to the increased risk of spontaneous life-threatening haemorrhage and the possible malignant transformation associated with larger-sized tumours, asymptomatic hepatic adenomas approaching 4 cm and those requiring hormonal therapy should also be resected.11
Yearly ultrasound imaging and serum AFP levels for patients with hepatocellular adenomas who do not have a resection of the tumour.
Emergency hepatic arteriography and embolisation should be considered to control bleeding in high-risk surgical candidates.
Focal nodular hyperplasia12
Focal nodular hyperplasia is the second most common benign liver tumour.
It is a benign condition of the liver that is often discovered incidentally on radiological investigation. It is more common in women.
It is not prone to malignant change.13
It is rarely symptomatic and surgical intervention is almost never required. However, symptomatic focal nodular hyperplasia does occur, may have rapid growth and may require resection.14
Duplex Doppler ultrasound may be sufficient but further confirmation may be required using CT, MRI, MR angiography or radionuclide imaging.
Rupture and haemorrhage have occasionally been reported. Therefore, some authorities advocate excision but most patients can be monitored with imaging.
Other benign liver tumours
They are very rare. They include fibroma, lipoma, leiomyoma and cystadenoma.
Mises à jour exclusives pour les professionnels de la santé
Restez informé des dernières mises à jour cliniques, des perspectives professionnelles et des conseils fondés sur des preuves. La newsletter Patient Pro sélectionne des contenus essentiels pour les professionnels de santé—livrés directement dans votre boîte de réception.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.
Lectures complémentaires et références
- EASL Clinical Practice Guidelines on the management of benign liver tumours; Association Européenne pour l'Étude du Foie (2016)
- Oldhafer KJ, Habbel V, Horling K, et al; Benign Liver Tumors. Visc Med. 2020 Aug;36(4):292-303. doi: 10.1159/000509145. Epub 2020 Aug 4.
- Yang JD, Hainaut P, Gores GJ, et al; Une vue globale du carcinome hépatocellulaire : tendances, risques, prévention et gestion. Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
- Bajenaru N, Balaban V, Savulescu F, et al; Hepatic hemangioma -review. J Med Life. 2015;8 Spec Issue:4-11.
- Ponnatapura J, Kielar A, Burke LMB, et al; Hepatic complications of oral contraceptive pills and estrogen on MRI: Controversies and update - Adenoma and beyond. Magn Reson Imaging. 2019 Jul;60:110-121. doi: 10.1016/j.mri.2019.04.010. Epub 2019 Apr 19.
- Leon M, Chavez L, Surani S; Hepatic hemangioma: What internists need to know. World J Gastroenterol. 2020 Jan 7;26(1):11-20. doi: 10.3748/wjg.v26.i1.11.
- Jia K, Gao Z, Li M, et al; Interventional treatments for hepatic hemangioma: A state-of-the-art review. J Interv Med. 2022 Feb 26;5(1):6-9. doi: 10.1016/j.jimed.2021.12.009. eCollection 2022 Feb.
- Szor DJ, Ursoline M, Herman P; Hepatic adenoma. Arq Bras Cir Dig. 2013 Jul-Sep;26(3):219-22.
- Socas L, Zumbado M, Perez-Luzardo O, et al; Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005 May;39(5):e27.
- Shreenath AP, Kahloon A; Hepatic Adenoma.
- Renzulli M, Clemente A, Tovoli F, et al; Hepatocellular adenoma: An unsolved diagnostic enigma. World J Gastroenterol. 2019 May 28;25(20):2442-2449. doi: 10.3748/wjg.v25.i20.2442.
- Klompenhouwer AJ, de Man RA, Dioguardi Burgio M, et al; New insights in the management of Hepatocellular Adenoma. Liver Int. 2020 Jul;40(7):1529-1537. doi: 10.1111/liv.14547. Epub 2020 Jun 11.
- Deneve JL, Pawlik TM, Cunningham S, et al; Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009 Mar;16(3):640-8. Epub 2009 Jan 8.
- Hamad S, Willyard CE, Mukherjee S; Focal Nodular Hyperplasia.
- Navarro AP, Gomez D, Lamb CM, et al; Focal nodular hyperplasia: a review of current indications for and outcomes of hepatic resection. HPB (Oxford). 2014 Jun;16(6):503-11. doi: 10.1111/hpb.12169. Epub 2013 Oct 15.
- Hsee LC, McCall JL, Koea JB; Focal nodular hyperplasia: what are the indications for resection? HPB (Oxford). 2005;7(4):298-302.
À propos de l'auteurVoir la biographie complète

Dr Hayley Willacy, FRCGP
Médecin généraliste, Auteur médical
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
Le Dr Hayley Willacy était médecin généraliste au NHS travaillant dans le nord-ouest de l'Angleterre, qui a pris sa retraite de la pratique clinique en 2022 après 30 ans.
À propos du critiqueVoir la biographie complète

Dr Toni Hazell, MRCGP
MBBS, BSc, MRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
Le Dr Toni Hazell a obtenu son diplôme de l'École de médecine de l'hôpital St. Mary et a effectué son VTS à l'hôpital Northwick Park.
Historique de l'article
Les informations sur cette page sont rédigées et examinées par des cliniciens qualifiés.
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
Prochaine révision prévue : 28 déc. 2027
29 déc. 2022 | Dernière version

Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.

Vous ne vous sentez pas bien ?
Évaluez vos symptômes en ligne gratuitement
Plus en oncologie
- Tumeurs ovariennes bénignes
- Moelle osseuse et insuffisance médullaire
- Lymphome de Burkitt
- Leucémie lymphoïde chronique
- Cancer colorectal
- Dyspnée en soins palliatifs
- Cancer de l'endomètre
- Cancer du larynx
- Mastocytose et troubles des mastocytes
- Mycosis fongoïde et lymphomes cutanés à cellules T
- Syndromes myélodysplasiques
- Ulcération orale
- Gestion de la douleur en soins palliatifs
- Phaéochromocytome
- Lésions cutanées pigmentées
- Radiothérapie
- Rétinoblastome
- Carcinome épidermoïde de la peau
- Cancer de la vulve et néoplasie intraépithéliale vulvaire
- Syndrome de Zollinger-Ellison